Cargando…

The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes

Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were...

Descripción completa

Detalles Bibliográficos
Autores principales: M’kacher, Radhia, Cuceu, Corina, Al Jawhari, Mustafa, Morat, Luc, Frenzel, Monika, Shim, Grace, Lenain, Aude, Hempel, William M., Junker, Steffen, Girinsky, Theodore, Colicchio, Bruno, Dieterlen, Alain, Heidingsfelder, Leonhard, Borie, Claire, Oudrhiri, Noufissa, Bennaceur-Griscelli, Annelise, Moralès, Olivier, Renaud, Sarah, Van de Wyngaert, Zoé, Jeandidier, Eric, Delhem, Nadira, Carde, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025489/
https://www.ncbi.nlm.nih.gov/pubmed/29848986
http://dx.doi.org/10.3390/cancers10060169
_version_ 1783336291548528640
author M’kacher, Radhia
Cuceu, Corina
Al Jawhari, Mustafa
Morat, Luc
Frenzel, Monika
Shim, Grace
Lenain, Aude
Hempel, William M.
Junker, Steffen
Girinsky, Theodore
Colicchio, Bruno
Dieterlen, Alain
Heidingsfelder, Leonhard
Borie, Claire
Oudrhiri, Noufissa
Bennaceur-Griscelli, Annelise
Moralès, Olivier
Renaud, Sarah
Van de Wyngaert, Zoé
Jeandidier, Eric
Delhem, Nadira
Carde, Patrice
author_facet M’kacher, Radhia
Cuceu, Corina
Al Jawhari, Mustafa
Morat, Luc
Frenzel, Monika
Shim, Grace
Lenain, Aude
Hempel, William M.
Junker, Steffen
Girinsky, Theodore
Colicchio, Bruno
Dieterlen, Alain
Heidingsfelder, Leonhard
Borie, Claire
Oudrhiri, Noufissa
Bennaceur-Griscelli, Annelise
Moralès, Olivier
Renaud, Sarah
Van de Wyngaert, Zoé
Jeandidier, Eric
Delhem, Nadira
Carde, Patrice
author_sort M’kacher, Radhia
collection PubMed
description Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30−/CD15− cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10(−3)), event-free survival (p < 10(−4)), and freedom from progression (p < 10(−3)) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients.
format Online
Article
Text
id pubmed-6025489
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60254892018-07-09 The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes M’kacher, Radhia Cuceu, Corina Al Jawhari, Mustafa Morat, Luc Frenzel, Monika Shim, Grace Lenain, Aude Hempel, William M. Junker, Steffen Girinsky, Theodore Colicchio, Bruno Dieterlen, Alain Heidingsfelder, Leonhard Borie, Claire Oudrhiri, Noufissa Bennaceur-Griscelli, Annelise Moralès, Olivier Renaud, Sarah Van de Wyngaert, Zoé Jeandidier, Eric Delhem, Nadira Carde, Patrice Cancers (Basel) Article Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30−/CD15− cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10(−3)), event-free survival (p < 10(−4)), and freedom from progression (p < 10(−3)) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients. MDPI 2018-05-30 /pmc/articles/PMC6025489/ /pubmed/29848986 http://dx.doi.org/10.3390/cancers10060169 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
M’kacher, Radhia
Cuceu, Corina
Al Jawhari, Mustafa
Morat, Luc
Frenzel, Monika
Shim, Grace
Lenain, Aude
Hempel, William M.
Junker, Steffen
Girinsky, Theodore
Colicchio, Bruno
Dieterlen, Alain
Heidingsfelder, Leonhard
Borie, Claire
Oudrhiri, Noufissa
Bennaceur-Griscelli, Annelise
Moralès, Olivier
Renaud, Sarah
Van de Wyngaert, Zoé
Jeandidier, Eric
Delhem, Nadira
Carde, Patrice
The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title_full The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title_fullStr The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title_full_unstemmed The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title_short The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
title_sort transition between telomerase and alt mechanisms in hodgkin lymphoma and its predictive value in clinical outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025489/
https://www.ncbi.nlm.nih.gov/pubmed/29848986
http://dx.doi.org/10.3390/cancers10060169
work_keys_str_mv AT mkacherradhia thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT cuceucorina thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT aljawharimustafa thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT moratluc thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT frenzelmonika thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT shimgrace thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT lenainaude thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT hempelwilliamm thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT junkersteffen thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT girinskytheodore thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT colicchiobruno thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT dieterlenalain thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT heidingsfelderleonhard thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT borieclaire thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT oudrhirinoufissa thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT bennaceurgriscelliannelise thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT moralesolivier thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT renaudsarah thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT vandewyngaertzoe thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT jeandidiereric thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT delhemnadira thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT cardepatrice thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT mkacherradhia transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT cuceucorina transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT aljawharimustafa transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT moratluc transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT frenzelmonika transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT shimgrace transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT lenainaude transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT hempelwilliamm transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT junkersteffen transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT girinskytheodore transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT colicchiobruno transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT dieterlenalain transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT heidingsfelderleonhard transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT borieclaire transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT oudrhirinoufissa transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT bennaceurgriscelliannelise transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT moralesolivier transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT renaudsarah transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT vandewyngaertzoe transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT jeandidiereric transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT delhemnadira transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes
AT cardepatrice transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes